Ownership Summary
InMed Pharmaceuticals Inc. (NASDAQ:INM) currently has 8 active institutional owners and shareholders as of today (September 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).
- These investors collectively held 23.8% of the company's total shares outstanding in September 2025, up from 0.2% in June 2025.
- On a quarter-over-quarter basis, institutional holdings shifted by 98788.60%, with a year-over-year a decrease of 50.00% in the count of filers.
- Of these 8 institutional investors, 5 increased their holdings in InMed Pharmaceuticals, while 0 of them reduced positions, and 3 investors maintained their exposure.
- The total number of shares held by institutions in InMed Pharmaceuticals increased to 303.59K as of September 2025, a net change of up by 303.28K shares quarter on quarter, and down 838.43K shares year over year.
- With 220.00K shares, SABBY MANAGEMENT, LLC commands the largest institutional position in InMed Pharmaceuticals as of September 30, 2025, equating to 17.28% of the company.
- Among the most significant buyers of InMed Pharmaceuticals during September 2025 were SABBY MANAGEMENT, LLC (220.00K), DRW Securities, LLC (35.87K), Virtu Financial LLC (20.37K), RENAISSANCE TECHNOLOGIES LLC (16.80K), THOMPSON DAVIS & CO., INC. (10.25K).
- The top 8 institutional holders of InMed Pharmaceuticals for the quarter ending September 2025 included SABBY MANAGEMENT, LLC (220.00K), DRW Securities, LLC (35.87K), Virtu Financial LLC (20.37K), RENAISSANCE TECHNOLOGIES LLC (16.80K), THOMPSON DAVIS & CO., INC. (10.25K), SBI Securities Co., Ltd. (300), Banque Cantonale Vaudoise (6), Federation des caisses Desjardins du Quebec (1).